Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 12/20 | 0.72 |
| ▸ | KDR | P35968 | 6/20 | 0.67 |
| ▸ | RET | P07949 | 4/20 | 0.67 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.67 |
| ▸ | ABL1 | P00519 | 3/20 | 0.67 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.67 |
| ▸ | MAP3K20 | Q9NYL2 | 3/20 | 0.67 |
| ▸ | SRC | P12931 | 3/20 | 0.67 |
| ▸ | PLK4 | O00444 | 2/20 | 0.67 |
| ▸ | AURKA | O14965 | 2/20 | 0.67 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.67 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.67 |
| ▸ | LCK | P06239 | 2/20 | 0.67 |
| ▸ | FYN | P06241 | 2/20 | 0.67 |
| ▸ | LYN | P07948 | 2/20 | 0.67 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.67 |
| ▸ | AXL | P30530 | 2/20 | 0.67 |
| ▸ | FRK | P42685 | 2/20 | 0.67 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.67 |
| ▸ | BLK | P51451 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2332792 | 0.93 | RAF1 (0.62) | RAF1KDRRETMAPK14ABL1 | |
| SCHEMBL2335397 | 0.92 | RAF1 (0.73) | RAF1KDRRETMAPK14ABL1 | |
| SCHEMBL15574587 | 0.90 | DDR2 (0.63) | RAF1KDRRETMAPK14ABL1 | |
| SCHEMBL12391533 | 0.88 | RAF1 (0.74) | RAF1KDRRETMAPK14ABL1 | |
| SCHEMBL30667524 | 0.88 | RAF1 (0.69) | RAF1KDRRETMAPK14ABL1 | |
| SCHEMBL2335526 | 0.88 | RAF1 (0.69) | RAF1KDRRETMAPK14ABL1 | |
| SCHEMBL2334638 | 0.88 | ALDH1A1 (0.63) | RAF1KDRRETMAPK14ABL1 | |
| SCHEMBL2333147 | 0.88 | KDR (0.73) | RAF1KDRRETMAPK14ABL1 | |
| SCHEMBL2334842 | 0.87 | RAF1 (0.70) | RAF1KDRRETMAPK14ABL1 | |
| SCHEMBL14396884 | 0.86 | KDR (0.66) | RAF1KDRRETMAPK14ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003657-B2 | Heterocyclic substituted bisarylurea derivatives | MERCK PATENT GMBH (DE) | 2011-08-23 | — | — | US | claimed |
| US-20090215799-A1 | HETEROCYCLIC SUBSTITUTED BISARYLUREA DERIVATIVES | MERCK PATENT GMBH | 2009-08-27 | — | — | US | claimed |
| EP-1799669-A1 | HETEROCYCLIC SUBSTITUTED BISARYLUREA DERIVATIVES AS KINASE INHIBITORS | Merck Patent GmbH (DE) | 2007-06-27 | — | — | EP | claimed |
| WO-2006040056-A1 | HETEROCYCLIC SUBSTITUTED BISARYLUREA DERIVATIVES AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2006-04-20 | — | — | WO | claimed |
| WO-2023222332-A1 | DIPHENYL UREAS FOR THE TREATMENT OF VIRAL INFECTIONS | MERCK PATENT GMBH (DE) | 2023-11-23 | — | — | WO | disclosed |
| US-8003657-B2 | Heterocyclic substituted bisarylurea derivatives | MERCK PATENT GMBH (DE) | 2011-08-23 | — | — | US | disclosed |
| US-8003657-B2 | Heterocyclic substituted bisarylurea derivatives | MERCK PATENT GMBH (DE) | 2011-08-23 | — | — | US | disclosed |
| US-8003657-B2 | Heterocyclic substituted bisarylurea derivatives | MERCK PATENT GMBH (DE) | 2011-08-23 | — | — | US | disclosed |
| US-20090215799-A1 | HETEROCYCLIC SUBSTITUTED BISARYLUREA DERIVATIVES | MERCK PATENT GMBH | 2009-08-27 | — | — | US | disclosed |
| US-20090215799-A1 | HETEROCYCLIC SUBSTITUTED BISARYLUREA DERIVATIVES | MERCK PATENT GMBH | 2009-08-27 | — | — | US | disclosed |
| US-20090215799-A1 | HETEROCYCLIC SUBSTITUTED BISARYLUREA DERIVATIVES | MERCK PATENT GMBH | 2009-08-27 | — | — | US | disclosed |
| US-20090124633-A1 | N-OXIDES OF HETEROCYCLIC SUBSTITUTED BISARYLUREAS FOR TREATING KINASE-MEDIATED DISEASES | MERCK PATENT GESELLSCHAFT (DE) | 2009-05-14 | — | — | US | disclosed |
| US-20090124633-A1 | N-OXIDES OF HETEROCYCLIC SUBSTITUTED BISARYLUREAS FOR TREATING KINASE-MEDIATED DISEASES | MERCK PATENT GESELLSCHAFT (DE) | 2009-05-14 | — | — | US | disclosed |
| US-20090124633-A1 | N-OXIDES OF HETEROCYCLIC SUBSTITUTED BISARYLUREAS FOR TREATING KINASE-MEDIATED DISEASES | MERCK PATENT GESELLSCHAFT (DE) | 2009-05-14 | — | — | US | disclosed |
| EP-2004631-A1 | N-OXIDES OF HETEROCYCLIC SUBSTITUTED BISARYLUREAS FOR TREATING KINASE-MEDIATED DISEASES | Merck Patent GmbH (DE) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007115670-A1 | N-OXIDES OF HETEROCYCLIC SUBSTITUTED BISARYLUREAS FOR TREATING KINASE-MEDIATED DISEASES | MERCK PATENT GMBH (DE) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007115670-A1 | N-OXIDES OF HETEROCYCLIC SUBSTITUTED BISARYLUREAS FOR TREATING KINASE-MEDIATED DISEASES | MERCK PATENT GMBH (DE) | 2007-10-18 | — | — | WO | disclosed |
| EP-1799669-A1 | HETEROCYCLIC SUBSTITUTED BISARYLUREA DERIVATIVES AS KINASE INHIBITORS | Merck Patent GmbH (DE) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006040056-A1 | HETEROCYCLIC SUBSTITUTED BISARYLUREA DERIVATIVES AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124633-A1 | N-OXIDES OF HETEROCYCLIC SUBSTITUTED BISARYLUREAS FOR TREATING KINASE-MEDIATED DISEASES | ABL1, NME2, MAP3K1 | RAF1 49/4885KDR 993/4885RET 160/4885 |
| US-20090215799-A1 | HETEROCYCLIC SUBSTITUTED BISARYLUREA DERIVATIVES | ABL1, BTK, PRKACA | RAF1 23/4885KDR 967/4885RET 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.